Home > Publications Database > Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. > print

001     157801
005     20250326091426.0
024 7 _ |a 10.1002/mds.28424
|2 doi
024 7 _ |a pmid:33332647
|2 pmid
024 7 _ |a pmc:PMC8247308
|2 pmc
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:96221795
|2 altmetric
037 _ _ |a DZNE-2021-01258
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Nissen, Sara Konstantin
|0 0000-0003-4711-0875
|b 0
245 _ _ |a Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
260 _ _ |a New York, NY
|c 2021
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742897179_24043
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease (PD) is a neurodegenerative disorder with a significant immune component, as demonstrated by changes in immune biomarkers in patients' biofluids. However, which specific cells are responsible for those changes is unclear because most immune biomarkers can be produced by various cell types.The aim of this study was to explore monocyte involvement in PD.We investigated the monocyte-specific biomarker sCD163, the soluble form of the receptor CD163, in cerebrospinal fluid (CSF) and serum in two experiments, and compared it with other biomarkers and clinical data. Potential connections between CD163 and alpha-synuclein were studied in vitro.CSF-sCD163 increased in late-stage PD and correlated with the PD biomarkers alpha-synuclein, Tau, and phosphorylated Tau, whereas it inversely correlated with the patients' cognitive scores, supporting monocyte involvement in neurodegeneration and cognition in PD. Serum-sCD163 increased only in female patients, suggesting a sex-distinctive monocyte response. CSF-sCD163 also correlated with molecules associated with adaptive and innate immune system activation and with immune cell recruitment to the brain. Serum-sCD163 correlated with proinflammatory cytokines and acute-phase proteins, suggesting a relation to chronic systemic inflammation. Our in vitro study showed that alpha-synuclein activates macrophages and induces shedding of sCD163, which in turn enhances alpha-synuclein uptake by myeloid cells, potentially participating in its clearance.Our data present sCD163 as a potential cognition-related biomarker in PD and suggest a role for monocytes in both peripheral and brain immune responses. This may be directly related to alpha-synuclein's proinflammatory capacity but could also have consequences for alpha-synuclein processing. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a alpha-synuclein
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a cognition
|2 Other
650 _ 7 |a monocytes
|2 Other
650 _ 7 |a sCD163
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Antigens, CD
|2 NLM Chemicals
650 _ 7 |a Antigens, Differentiation, Myelomonocytic
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a CD163 antigen
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a Receptors, Cell Surface
|2 NLM Chemicals
650 _ 7 |a alpha-Synuclein
|2 NLM Chemicals
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Antigens, CD
|2 MeSH
650 _ 2 |a Antigens, Differentiation, Myelomonocytic
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognition
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Monocytes
|2 MeSH
650 _ 2 |a Parkinson Disease: complications
|2 MeSH
650 _ 2 |a Peptide Fragments
|2 MeSH
650 _ 2 |a Receptors, Cell Surface
|2 MeSH
650 _ 2 |a alpha-Synuclein
|2 MeSH
700 1 _ |a Ferreira, Sara Almeida
|b 1
700 1 _ |a Nielsen, Marlene Christina
|b 2
700 1 _ |a Schulte, Claudia
|0 P:(DE-2719)9000366
|b 3
|u dzne
700 1 _ |a Shrivastava, Kalpana
|b 4
700 1 _ |a Hennig, Dorle
|b 5
700 1 _ |a Etzerodt, Anders
|b 6
700 1 _ |a Graversen, Jonas Heilskov
|b 7
700 1 _ |a Berg, Daniela
|0 P:(DE-2719)2000059
|b 8
|u dzne
700 1 _ |a Maetzler, Walter
|0 P:(DE-2719)2810915
|b 9
|u dzne
700 1 _ |a Panhelainen, Anne
|b 10
700 1 _ |a Møller, Holger Jon
|b 11
700 1 _ |a Brockmann, Kathrin
|0 P:(DE-2719)2811916
|b 12
|u dzne
700 1 _ |a Romero-Ramos, Marina
|0 0000-0003-0970-578X
|b 13
|e Corresponding author
773 _ _ |a 10.1002/mds.28424
|g Vol. 36, no. 4, p. 963 - 976
|0 PERI:(DE-600)2041249-6
|n 4
|p 963 - 976
|t Movement disorders
|v 36
|y 2021
|x 1531-8257
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/157801/files/DZNE-2021-01258.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/157801/files/DZNE-2021-01258.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:157801
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000366
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000059
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)2810915
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811916
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)5000055
|k AG Berg
|l Parkinson's Disease Genetics
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000055
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21